Rhythm Pharmaceuticals, Inc.(Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the publication of previously disclosed results from its Phase 2 study of setmelanotide for the treatment of hypothalamic obesity.

Rhythm Pharmaceuticals, Inc.（纳斯达克：RYTM）是一家全球商业化阶段的生物制药公司，专注于改变患有罕见神经内分泌疾病的患者及其家属的生活，今天宣布公布了先前披露的用于治疗下丘脑肥胖的setmelanotide第二阶段研究的结果。

The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology. “People with hypothalamic obesity experience rapid, severe weight gain and hyperphagia,” said lead author Christian Roth, M.D., Seattle Children’s Research Institute and Division of Endocrinology, Department of Pediatrics, University of Washington.

这些数据发表在同行评议的《柳叶刀糖尿病与内分泌学》杂志上。华盛顿大学西雅图儿童研究所和内分泌学系的首席作者克里斯蒂安·罗斯医学博士说：“患有下丘脑肥胖的人会经历快速、严重的体重增加和食欲亢进。”。

“In this first study to investigate the use of setmelanotide as a targeted treatment for hypothalamic obesity, we observed a consistent reduction in body weight and hunger in all adherent patients. We believe these findings support setmelanotide as a potential novel and effective treatment option, and we look forward to potentially confirming the results in the ongoing pivotal study.” Acquired hypothalamic obesity is a rare form of extreme obesity that occurs following damage to the hypothalamic region of the brain, which includes the melanocortin-4 receptor (MC4R) pathway and is responsible for controlling physiological functions such as hunger and weight regulation.

“在这项首次研究使用setmelanotide作为下丘脑肥胖的靶向治疗方法的研究中，我们观察到所有依从患者的体重和饥饿感持续下降。我们相信这些发现支持setmelanotide作为一种潜在的新型有效治疗选择，我们期待着在正在进行的关键研究中可能证实结果。”获得性下丘脑肥胖是一种罕见的极端肥胖形式，发生在大脑下丘脑区域受损后，其中包括黑皮质素-4受体（MC4R）途径，并负责控制饥饿和体重调节等生理功能。

It most frequently follows the growth or surgical removal of craniopharyngioma, astrocytoma, or other rare brain tumors.

它最常见于颅咽管瘤，星形细胞瘤或其他罕见脑肿瘤的生长或手术切除。